Status:
COMPLETED
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
Lead Sponsor:
Pfizer
Conditions:
Overactive Bladder Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The trial consisted of a 2 week Run-In period, 12 week double-blind Treatment period and 2 week Safety Follow-Up period. Subjects were randomized to one of 4 treatment arms receiving either fesoterodi...
Eligibility Criteria
Inclusion
- Overactive Bladder Syndrome
Exclusion
- less than 8 micturitions in 24 hours
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00220363
Start Date
January 1 2004
End Date
February 1 2005
Last Update
May 5 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
Monheim, Germany